Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Horsdal, Henriette T ; Johnsen, Søren Paaske ; Søndergaard, Flemming ; Jacobsen, Jacob ; Thomsen, Reimar W ; Schmitz, Ole ; Sørensen, Henrik T ; Rungby, Jørgen. / Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. In: Diabetes - Metabolism: Research and Reviews (Print Edition). 2009 ; Vol. 25, No. 6. pp. 515-522.

Bibtex

@article{ffc0530db96e43f1a277821229d0c43b,
title = "Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study",
abstract = "BACKGROUND: The cardiovascular safety, including risk of myocardial infarction (MI), of individual sulfonylureas (SUs) may differ. It remains uncertain whether treatment with individual SUs influences prognosis following MI. METHODS: We conducted a nationwide population-based follow-up study among all Danish patients hospitalized with first-time MI from 1996 to 2004. From the national health databases, we identified 3930 MI patients who used SUs at the time of admission. We computed mortality rates and rates of MI and heart failure readmission according to type of SU and used Cox's proportional hazards regression analysis to compute hazard ratios (HRs) as estimates of relative risk controlling for differences in prognostic covariates. RESULTS: The 30-day and 1-year mortality after MI among SU users was 22.0% and 35.3%, respectively. We found no substantial differences in 30-day and 1-year mortality among users of different SUs. Use of gliclazide in monotherapy showed a trend towards lower mortality; adjusted HR of 1-year mortality 0.70 (95% CI: 0.48-1.00). Users of the different SUs appeared to have similar risks of new MI and heart failure following MI. CONCLUSIONS: The prognosis after MI was not substantially influenced by the choice of SU.",
author = "Horsdal, {Henriette T} and Johnsen, {S{\o}ren Paaske} and Flemming S{\o}ndergaard and Jacob Jacobsen and Thomsen, {Reimar W} and Ole Schmitz and S{\o}rensen, {Henrik T} and J{\o}rgen Rungby",
year = "2009",
doi = "10.1002/dmrr.971",
language = "English",
volume = "25",
pages = "515--522",
journal = "Diabetes - Metabolism: Research and Reviews",
issn = "1520-7552",
publisher = "John/Wiley & Sons Ltd",
number = "6",

}

RIS

TY - JOUR

T1 - Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study

AU - Horsdal, Henriette T

AU - Johnsen, Søren Paaske

AU - Søndergaard, Flemming

AU - Jacobsen, Jacob

AU - Thomsen, Reimar W

AU - Schmitz, Ole

AU - Sørensen, Henrik T

AU - Rungby, Jørgen

PY - 2009

Y1 - 2009

N2 - BACKGROUND: The cardiovascular safety, including risk of myocardial infarction (MI), of individual sulfonylureas (SUs) may differ. It remains uncertain whether treatment with individual SUs influences prognosis following MI. METHODS: We conducted a nationwide population-based follow-up study among all Danish patients hospitalized with first-time MI from 1996 to 2004. From the national health databases, we identified 3930 MI patients who used SUs at the time of admission. We computed mortality rates and rates of MI and heart failure readmission according to type of SU and used Cox's proportional hazards regression analysis to compute hazard ratios (HRs) as estimates of relative risk controlling for differences in prognostic covariates. RESULTS: The 30-day and 1-year mortality after MI among SU users was 22.0% and 35.3%, respectively. We found no substantial differences in 30-day and 1-year mortality among users of different SUs. Use of gliclazide in monotherapy showed a trend towards lower mortality; adjusted HR of 1-year mortality 0.70 (95% CI: 0.48-1.00). Users of the different SUs appeared to have similar risks of new MI and heart failure following MI. CONCLUSIONS: The prognosis after MI was not substantially influenced by the choice of SU.

AB - BACKGROUND: The cardiovascular safety, including risk of myocardial infarction (MI), of individual sulfonylureas (SUs) may differ. It remains uncertain whether treatment with individual SUs influences prognosis following MI. METHODS: We conducted a nationwide population-based follow-up study among all Danish patients hospitalized with first-time MI from 1996 to 2004. From the national health databases, we identified 3930 MI patients who used SUs at the time of admission. We computed mortality rates and rates of MI and heart failure readmission according to type of SU and used Cox's proportional hazards regression analysis to compute hazard ratios (HRs) as estimates of relative risk controlling for differences in prognostic covariates. RESULTS: The 30-day and 1-year mortality after MI among SU users was 22.0% and 35.3%, respectively. We found no substantial differences in 30-day and 1-year mortality among users of different SUs. Use of gliclazide in monotherapy showed a trend towards lower mortality; adjusted HR of 1-year mortality 0.70 (95% CI: 0.48-1.00). Users of the different SUs appeared to have similar risks of new MI and heart failure following MI. CONCLUSIONS: The prognosis after MI was not substantially influenced by the choice of SU.

U2 - 10.1002/dmrr.971

DO - 10.1002/dmrr.971

M3 - Journal article

VL - 25

SP - 515

EP - 522

JO - Diabetes - Metabolism: Research and Reviews

JF - Diabetes - Metabolism: Research and Reviews

SN - 1520-7552

IS - 6

ER -

ID: 64965469